Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Non Operating Income (2018 - 2025)

Cue Biopharma (CUE) has disclosed Non Operating Income for 8 consecutive years, with $107000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 21.9% to $107000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $449000.0 through Dec 2025, down 45.58% year-over-year, with the annual reading at $450000.0 for FY2025, 45.52% down from the prior year.
  • Non Operating Income hit $107000.0 in Q4 2025 for Cue Biopharma, down from $147000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $414000.0 in Q3 2023 to a low of -$118000.0 in Q2 2022.
  • Historically, Non Operating Income has averaged $148494.9 across 5 years, with a median of $142000.0 in 2024.
  • Biggest YoY gain for Non Operating Income was 6929.25% in 2022; the steepest drop was 591.67% in 2022.
  • Year by year, Non Operating Income stood at $3898.0 in 2021, then surged by 6929.25% to $274000.0 in 2022, then skyrocketed by 45.26% to $398000.0 in 2023, then tumbled by 65.58% to $137000.0 in 2024, then fell by 21.9% to $107000.0 in 2025.
  • Business Quant data shows Non Operating Income for CUE at $107000.0 in Q4 2025, $147000.0 in Q3 2025, and $153000.0 in Q2 2025.